Kevin James, MD
Geriatric Medicine · Maryville, TNNPI 1013176023
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations.
Across 242 payments — averaging $18.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$470
- Novo Nordisk$459
- Pfizer$428
- Neurocrine Biosciences, Inc.$274
- GSK$266
- Lilly USA, LLC$216
- plus $2K from 34 others
What the payments were for
- Food & beverage$4,391100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $470 |
| Novo Nordisk | 27 | $459 |
| Pfizer | 26 | $428 |
| Neurocrine Biosciences, Inc. | 13 | $274 |
| GSK | 15 | $266 |
| Lilly USA, LLC | 13 | $216 |
| Otsuka America Pharmaceutical, Inc. | 9 | $179 |
| Eisai Inc. | 8 | $174 |
| E.r. Squibb & Sons, L.L.C. | 11 | $172 |
| Bayer | 10 | $151 |
| AstraZeneca | 9 | $149 |
| Sumitomo Pharma America, Inc. | 6 | $115 |
| Corium, LLC | 6 | $112 |
| Merck | 6 | $95 |
| La Jolla Pharmaceutical Company | 5 | $89 |
| Xeris Pharmaceuticals, Inc. | 5 | $81 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $77 |
| UCB, Inc. | 3 | $76 |
| AbbVie(2 entities) | 4 | $76 |
| Sunovion Pharmaceuticals Inc. | 4 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $66 |
| Johnson & Johnson | 4 | $65 |
| Astellas Pharma US Inc | 3 | $53 |
| Lundbeck LLC | 2 | $51 |
| Boehringer Ingelheim | 3 | $47 |
| Acadia Pharmaceuticals Inc | 3 | $39 |
| CMP Pharma, Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Kyowa Kirin, Inc. | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Boston Scientific | 1 | $25 |
| Inogen, Inc. | 1 | $25 |
| Organogenesis Inc. | 1 | $22 |
| Biogen | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$4,391 in reported general payments places this provider in the 85th percentile of 46 geriatric medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 166 | $185,738 |
| RybelsusSemaglutide | 23 | $43,218 |
| OzempicSemaglutide | 23 | $38,602 |
| JardianceEmpagliflozin | 26 | $27,067 |
| XareltoRivaroxaban | 25 | $25,667 |
| MyrbetriqMirabegron | 22 | $24,468 |
| TrulicityDulaglutide | 11 | $19,594 |
| ProliaDenosumab | 11 | $19,304 |
| FarxigaDapagliflozin Propanediol | 11 | $17,345 |
| GemtesaVibegron | 12 | $14,879 |
| Potassium Chloride | 193 | $4,298 |
| Atorvastatin Calcium | 354 | $3,421 |
| Mirtazapine | 117 | $3,355 |
| Memantine Hcl | 96 | $2,493 |
| Levothyroxine Sodium | 245 | $2,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $428 | $185,738166 claims |
| Novo NordiskRybelsus, Ozempic | $459 | $81,82046 claims |
| Boehringer IngelheimJardiance | $47 | $27,06726 claims |
| Johnson & JohnsonXarelto | $65 | $25,66725 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $24,46822 claims |
| Lilly USA, LLCTrulicity | $216 | $19,59411 claims |
| AmgenProlia | $18 | $19,30411 claims |
| AstraZenecaFarxiga | $149 | $17,34511 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $115 | $14,87912 claims |
| AbbVieSynthroid | $76 | $1,74713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 46 geriatric medicine providers in Tennessee.
Other geriatric medicine in Maryville
- Ronald HamdyJohnson City$69K
- Kenneth DozierMadison$9K
- Lotika PanditChattanooga$8K
- Terry MelvinChattanooga$7K
- Monica CraneKnoxville$7K
- Raul CouretHendersonville$6K
- Monica WarhaftigMemphis$3K
- Arundati RameshMurfreesboro$2K
- Kendra SheppardMemphis$985
- Karen RheaPowell$726
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.